cas 1513-87-7|| where to buy Bis(2,2,2-trifluoroethyl)carbonate (TFEC)

Produktname:Bis(2,2,2-trifluoroethyl)carbonate (TFEC)

IUPAC Name:

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM000259-10g	3-4 Weeks	ȯǫǫ
CM000259-25g	3-4 Weeks	ƃǫǫ
CM000259-100g	5-6 Weeks	Şǫȯȡ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1513-87-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1513-87-7; Molekulare Formel:C5H4F6O3; Schmelzpunkt:-; SMILES-Code:O=C(OCC(F)(F)F)OCC(F)(F)F; Dichte:

: Katalognummer:CM000259; Molekulargewicht:226.07; Siedepunkt:; Mdl-Nr.:MFCD11857845; Lagerung:

: Lithium-ion Battery Materials; Lithium-ion batteries (Li-ion batteries) are widely used in portable electronic devices, electric vehicles, and renewable energy storage systems due to their high energy density and long cycle life. These batteries are composed of several key materials such as cathode materials, anode materials, electrolyte, separator and current collector, which enable them to operate. Other minor components in Li-ion batteries include binders, additives, and fillers, which improve electrode stability, electrolyte performance, and battery safety. Ongoing research and development focus on improving the energy density, safety, and cost-effectiveness of Li-ion batteries through advancements in materials, including the exploration of new cathode and anode materials, solid-state electrolytes, high-voltage electrolyte additives, and advanced manufacturing techniques.

: Inavolisib; Genentech’s Phase III results show that the Inavolisib (GDC-0077) treatment meets the primary end point in hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated Breast Cancer. The combination of Inavolisib with Palbociclib and fulvestrant improves the progression-free survival (PFS) in the first line. Inavolisib is a potent selective inhibitor of PI3K alpha (PI3Kα) that binds to the ATP-binding site of p110α, and promotes the degradation of mutated p110α.